



Please renumber original page 168 to page 167.

**REMARKS**

Applicants have substituted a new Sequence Listing section according to 37 C.F.R. §§1.821-1.825 as new pages 150-157, and have renumbered pages 158-168 as new page numbers 157-167.

Attached hereto, as part of the specification, is a "Sequence Listing" on paper copy, in accordance with 37 C.F.R. §1.821(c), as well as a 5 1/4" floppy disk containing the "Sequence Listing" in computer readable form in accordance with 37 C.F.R. §1.821(e).

The following statement is provided to meet the requirements of 37 C.F.R. §1.821(f), 1.821(g) and 1.825(a).

I hereby state that the content of the paper and computer readable copies of the sequence listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are believed to be the same.

I hereby also state that the submission, filed in accordance with 37 C.F.R. §1.821(g), is not believed to include new matter.

I also hereby state that the Amendments, made in accordance with 37 C.F.R. §1.825(a), included in the substitute sheets of the sequence listing are believed to be supported in the application as filed.

I hereby also state that the substitute sheets of the sequence listing do not intentionally include new matter.

Accordingly, applicants submit that the present application contains patentable subject matter and therefore urge the examiner to pass the case to issuance.

In re USSN 08/192,861

If the examiner has any questions or comments concerning the above described application, the examiner is urged to contact the undersigned at the phone number below.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant(s)

By

  
G. Kevin Townsend  
Registration No. 34,033

GKT:al  
419 Seventh Street, N.W.  
Washington, D.C. 20004  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
\\user22\gkt\lelvil3e.pa



In re Application of: LE/VILCEK et al  
Serial No.: 08/192,861  
Filed: February 4, 1994  
For: ANTI-TNF ANTIBODIES AND PEPTIDES OF HUMAN TUMOR NECROSIS FACTOR

Art Unit: Box Sequence  
Examiner:  
Washington, D.C.  
Atty.'s Docket: LE1/VILCEK=3E  
Date: April 14, 1994

THE COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

Sir:

Transmitted herewith is a ☐ Amendment ☒ Prelim. Amend. & Stmt. \$1,821-1,825 w/ Seq. List + 5 1/4" disk in the above-identified application.

☐ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.

☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

☒ No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)	SMALL ENTITY		OR	OTHER THAN A SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE		RATE	ADDITIONAL FEE
TOTAL	*	MINUS	**	=	x 11	\$		x 22	\$
INDEP.	*	MINUS	***	=	x 37	\$		x 74	\$
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					+115	\$		+ 230	\$
					TOTAL	\$	OR	TOTAL	\$
					ADDITIONAL FEE	\$			

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

☐ First - \$ 55.00

☐ Second - \$180.00

☐ Third - \$420.00

☐ Fourth - \$660.00

Month After Time Period Set

☐ Please charge my Deposit Account No. 02-4035 in the amount of \$\_\_\_\_\_. A duplicate copy of this sheet is attached.

☐ A check in the amount of \$\_\_\_\_\_ is attached (check no. \_\_\_\_\_).

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

Facsimile: (202) 737-3528

Telephone: (202) 628-5197

By: G. Kevin Townsend

G. KEVIN TOWNSEND

Registration No. 34,033

GKT:al



Application No. 08/192861

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):



☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

☐ 7.  
Other: \_\_\_\_\_

**Applicant must provide:**



☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123  
For CRF submission help, call (703) 308-4212  
For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.